Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review

doi:10.5306/wjco.v8.i3.266

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7815)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

382

WORD

324

HTML

3350

Figures (1-3)

207

Tables (1-4)

213

Sum=4476

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1223

Download

2116

Sum=3339

Jun 10, 2017 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Oncol. Jun 10, 2017; 8(3): 266-272
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.266

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart of search and article selection process.

Open in New Tab Full Size Figure Download Figure

Figure 2 Funnel plots of randomized clinical trials comparing surgery alone or with additional chemotherapy for the treatment of patients with potentially resectable colorectal liver metastases. The HR was fit for overall survival. HR: Hazard ratio.

Open in New Tab Full Size Figure Download Figure

Figure 3 Linear prediction of overall survival according to recurrence free survival. The sizes of dots are proportional to weight of each study. The linear regression was based on linear prediction of OS HR according to RFS HR, along with a 95%CI based on the mean. RFS: Recurrence-free survival; OS: Overall survival; HR: Hazard ratio.

Citation: Araujo RLC, Herman P, Riechelmann RP. Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World J Clin Oncol 2017; 8(3): 266-272
URL: https://www.wjgnet.com/2218-4333/full/v8/i3/266.htm
DOI: https://dx.doi.org/10.5306/wjco.v8.i3.266